Literature DB >> 19307182

Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells.

Amalraj Thangasamy1, Jessica Rogge, Sudhakar Ammanamanchi.   

Abstract

Hypoxia-inducible factor-1alpha (HIF-1alpha) overexpression was shown to be associated with invasion and metastasis of tumors and tumor cell lines. The identification of molecular targets that contribute to HIF-1alpha-mediated invasion is under intensive investigation. We have analyzed the role of recepteur d'origine nantais (RON), a tyrosine kinase receptor for macrophage-stimulating protein (MSP) that plays a role in breast cancer cell invasion as one of the molecular targets of HIF-1alpha. Analysis of a panel of breast cancer cell lines indicated a correlation between HIF-1alpha and RON expression. Treatment of HIF-1alpha- and RON-positive breast cancer cells with HIF-1alpha inhibitor, echinomycin, led to the inhibition of HIF-1alpha activity and RON expression. We have identified HIF-1alpha binding site on the RON promoter. Chromatin immunoprecipitation analysis and site-directed mutagenesis of the RON promoter confirmed the binding of HIF-1alpha to RON promoter. HIF-1alpha inhibitor-, echinomycin-, or short hairpin RNA-mediated selective knockdown of HIF-1alpha or HIF-1alpha target RON tyrosine kinase abrogated RON gene expression, and the RON ligand macrophage-stimulating protein mediated invasion of breast cancer cells. Consequently, the data presented herein demonstrated RON as a novel molecular target of HIF-1alpha and suggest a potential therapeutic role for HIF-1alpha or RON tyrosine kinase inhibitors in the blockade of RON tyrosine kinase-mediated invasion of carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19307182      PMCID: PMC2682848          DOI: 10.1074/jbc.M809320200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation.

Authors:  Glendon M Zinser; Mike A Leonis; Kenya Toney; Peterson Pathrose; Megan Thobe; Sarah A Kader; Belinda E Peace; Shirelyn R Beauman; Margaret H Collins; Susan E Waltz
Journal:  Cancer Res       Date:  2006-12-15       Impact factor: 12.701

2.  Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.

Authors:  Dehe Kong; Eun Jung Park; Andrew G Stephen; Maura Calvani; John H Cardellina; Anne Monks; Robert J Fisher; Robert H Shoemaker; Giovanni Melillo
Journal:  Cancer Res       Date:  2005-10-01       Impact factor: 12.701

3.  Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.

Authors:  Reinhard Bos; Petra van der Groep; Astrid E Greijer; Avi Shvarts; Sybren Meijer; Herbert M Pinedo; Gregg L Semenza; Paul J van Diest; Elsken van der Wall
Journal:  Cancer       Date:  2003-03-15       Impact factor: 6.860

4.  Structure of the promoter for the human macrophage stimulating protein receptor gene.

Authors:  F Del Gatto; E Gilbert; C Ronsin; R Breathnach
Journal:  Biochim Biophys Acta       Date:  1995-07-25

5.  Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients.

Authors:  Jean-Philippe Dales; Stéphane Garcia; Séverine Meunier-Carpentier; Lucile Andrac-Meyer; Olivier Haddad; Marie-Noölle Lavaut; Claude Allasia; Pascal Bonnier; Colette Charpin
Journal:  Int J Cancer       Date:  2005-09-20       Impact factor: 7.396

6.  Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients.

Authors:  Wen-Ying Lee; Helen H W Chen; Nan-Haw Chow; Wu-Chou Su; Pin-Wen Lin; How-Ran Guo
Journal:  Clin Cancer Res       Date:  2005-03-15       Impact factor: 12.531

Review 7.  Hypoxia-inducible factor-1 in human breast and prostate cancer.

Authors:  K S Kimbro; J W Simons
Journal:  Endocr Relat Cancer       Date:  2006-09       Impact factor: 5.678

8.  Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response.

Authors:  Asa Kronblad; Karin Jirström; Lisa Rydén; Bo Nordenskjöld; Göran Landberg
Journal:  Int J Cancer       Date:  2006-05-15       Impact factor: 7.396

9.  Regulation of RON tyrosine kinase-mediated invasion of breast cancer cells.

Authors:  Amalraj Thangasamy; Jessica Rogge; Sudhakar Ammanamanchi
Journal:  J Biol Chem       Date:  2007-12-28       Impact factor: 5.157

10.  Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?

Authors:  Günther Gruber; Richard H Greiner; Ruslan Hlushchuk; Daniel M Aebersold; Hans J Altermatt; Gilles Berclaz; Valentin Djonov
Journal:  Breast Cancer Res       Date:  2004-03-09       Impact factor: 6.466

View more
  18 in total

1.  Isolation of Fully Human Antagonistic RON Antibodies Showing Efficient Block of Downstream Signaling and Cell Migration.

Authors:  Zeynep Gunes; Adriana Zucconi; Mario Cioce; Annalisa Meola; Monica Pezzanera; Stefano Acali; Immacolata Zampaglione; Valeria De Pratti; Luca Bova; Fabio Talamo; Anna Demartis; Paolo Monaci; Nicola La Monica; Gennaro Ciliberto; Alessandra Vitelli
Journal:  Transl Oncol       Date:  2011-02-01       Impact factor: 4.243

2.  Effects of PTCs on nonsense-mediated mRNA decay are dependent on PTC location.

Authors:  Heegyum Moon; Xuexiu Zheng; Tiing Jen Loh; Ha Na Jang; Yongchao Liu; Da-Woon Jung; Darren R Williams; Haihong Shen
Journal:  Oncol Lett       Date:  2017-01-19       Impact factor: 2.967

3.  Prognostic significance of MST1R dysregulation in renal cell tumors.

Authors:  Ana S Pires-Luís; Márcia Vieira-Coimbra; Maria João Ferreira; João Ramalho-Carvalho; Pedro Costa-Pinheiro; Luís Antunes; Paula C Dias; Francisco Lobo; Jorge Oliveira; Inês Graça; Rui Henrique; Carmen Jerónimo
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

Review 4.  MSP-RON signalling in cancer: pathogenesis and therapeutic potential.

Authors:  Hang-Ping Yao; Yong-Qing Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  Nat Rev Cancer       Date:  2013-07       Impact factor: 60.716

5.  Novel function of transcription factor Nrf2 as an inhibitor of RON tyrosine kinase receptor-mediated cancer cell invasion.

Authors:  Amalraj Thangasamy; Jessica Rogge; Naveen K Krishnegowda; James W Freeman; Sudhakar Ammanamanchi
Journal:  J Biol Chem       Date:  2011-07-28       Impact factor: 5.157

6.  An unusual function of RON receptor tyrosine kinase as a transcriptional regulator in cooperation with EGFR in human cancer cells.

Authors:  Hsiao-Sheng Liu; Pei-Yin Hsu; Ming-Derg Lai; Hong-Yi Chang; Chung-Liang Ho; Hong-Lin Cheng; Hsing-Ta Chen; Yan-Ju Lin; Tsung-Jung Wu; Tzong-Shin Tzai; Nan-Haw Chow
Journal:  Carcinogenesis       Date:  2010-05-24       Impact factor: 4.944

Review 7.  Discovery of Cell-Surface Vimentin (CSV) as a Sarcoma Target and Development of CSV-Targeted IL12 Immune Therapy.

Authors:  Izhar S Batth; Shulin Li
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

8.  Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1α levels under hypoxia.

Authors:  Astrid A Glück; Eleonora Orlando; Dominic Leiser; Michaela Poliaková; Lluís Nisa; Aurélie Quintin; Jacopo Gavini; Deborah M Stroka; Sabina Berezowska; Lukas Bubendorf; Andree Blaukat; Daniel M Aebersold; Michaela Medová; Yitzhak Zimmer
Journal:  Oncogene       Date:  2018-05-02       Impact factor: 9.867

Review 9.  Hypoxia-regulated target genes implicated in tumor metastasis.

Authors:  Ya-Ping Tsai; Kou-Juey Wu
Journal:  J Biomed Sci       Date:  2012-12-14       Impact factor: 8.410

10.  A potential signaling axis between RON kinase receptor and hypoxia-inducible factor-1 alpha in pancreatic cancer.

Authors:  Akihisa Kato; Serina Ng; Amalraj Thangasamy; Haiyong Han; Wendi Zhou; Stephane Raeppel; Michael Fallon; Sushovan Guha; Sudhakar Ammanamanchi
Journal:  Mol Carcinog       Date:  2021-08-04       Impact factor: 5.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.